RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval
With Blockbuster Sales Potential
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.
You may also be interested in...
Sanofi Sees Dupixent As Just The Start Of COPD Transformation
Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.
Sobi Exits Nirsevimab Cost-Sharing Pact With AstraZeneca, Simplifies Royalty Deal With Sanofi
Deal Snapshot: Approved in the EU/UK and nearing a US approval, rights to the RSV prophylaxis for infants and newborns are simplified in the pair of agreements unveiled by Synagis owner Sobi.
J&J Quits RSV Development With Two Rivals Already Poised For US Approval
The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.